Pediatrix Medical Group, Inc.
MDPediatrix Medical Group, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the price is already 53 weeks into its uptrend — timing risk, not thesis risk.
The price is in a confirmed uptrend (53 weeks in) while the P/E sits at the 45th percentile of its own 4-year range. Underneath, the last four quarters read improving — profit +50.0% year on year, and 141% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Pediatrix Medical Group, Inc. trades at $24.7, in a confirmed uptrend and 53 weeks into that stage. That is +11.4% against its own 200-day average. It sits at 81% of a 52-week range of $16 to $27. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 10 straight weeks.
Today the stock is in a confirmed uptrend — week 53 of stage 2. At $24.7 it trades +11.4% versus its 200-day average and sits at 81% of its 52-week range ($16–$27).
Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved −67% while the S&P 500 moved +263% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 10 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Pediatrix Medical Group, Inc. trades at 11.8× P/E, mid-range by its own standards (45th percentile). Its long-run median P/E is 12.0×, measured across 4.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 11.8× is mid-range by its own standards (45th percentile), against a long-run median of 12.0× measured over 4.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
The price move, decomposed: over 3y, of the +19.1%/yr price move, ~+20.8%/yr came from earnings growth and ~−1.7 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Improving Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Pediatrix Medical Group, Inc. reads as improving on its fundamental arc. Improving — profit growth bottomed 7 quarters ago at −100.0% and has held its recovery at +50.0% (single-quarter readings), ROCE lifting at 13.1%. The read is built from 12 quarters across 3 curves, on partial evidence.
Why it matters: a sustained climb off the trough is the setup this page is built to catch — the question moves to what you pay for it.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −5.0% | −1.0% | — | — |
| Profit | — | +34.4% | — | — |
| EPS | — | +37.9% | — | — |
| Stock price | +106.3% | +19.1% | −5.7% | −9.4% |
4-Factor Sector Score
43.3/100 — rank 21 of 30 in Medical Care Facilities · 74% evidence confidence
Pediatrix Medical Group, Inc. scores 43.3 out of 100 against the 30 companies it is compared with in Medical Care Facilities, ranking 21. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 17.5 + 10.2 + 9.9 + 5.7 = 43.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Pediatrix Medical Group, Inc. reported $0.5 B of revenue in the Mar 26 quarter, +4.3% year on year. Over 4 years it has compounded at 0.0% a year. The last full year, FY25, came in at $1.9 B. The last four reported quarters add to $1.9 B.
FY25 revenue came in at $1.9 B (−5.0% on the year), capping 4 years at 0.0% compound. The latest quarter (Mar 26) printed $0.5 B, +4.3% year on year.
Pace check: the last four quarters averaged −1.9% growth against the decade's 0.0% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −2.0% over the last 4 quarters against −2.0%/yr over the last 8 — stabilising.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Pediatrix Medical Group, Inc.'s operating margin is 8.3% in the Mar 26 quarter, +1.8 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −3.5% to 11.5%. The current quarter sits inside that band.
The latest quarter's operating margin is 8.3%, +1.8 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −3.5%–11.5%.
Why the margin moved: operating margin went +1.8 pp year on year while gross margin went +1.2 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Pediatrix Medical Group, Inc. earned $0.0 B of net profit in the Mar 26 quarter, +50.0% year on year. Full-year FY25 profit was $0.2 B. The 4-year compound rate is 6.9%. That is 6.3% of the quarter's revenue. The same quarter a year earlier earned $0.0 B. 2 of the last 12 reported quarters were loss-making.
Mar 26 profit was $0.0 B, +50.0% year on year. On the full year, FY25 printed $0.2 B (null), and the 4-year compound rate is 6.9%.
Why profit moved: revenue contributed +4.3% and the margin +1.8 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +100.0% vs revenue −1.9%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 141% of Pediatrix Medical Group, Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $0.3 B of operating cash against $0.2 B of profit. After $0.0 B of capital spending, $0.3 B was left as free cash.
FY25: operating cash of $0.3 B against reported profit of $0.2 B, leaving free cash of $0.3 B after $0.0 B of capital spending. Across the last 3 fiscal years the conversion rate is 141% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Pediatrix Medical Group, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Pediatrix Medical Group, Inc. earns a ROE of 20% in FY25. That is up from a trough of −13% in FY24. Return on invested capital clears the cost of that capital by +9.3 percentage points, so growth here adds value rather than only size. The wiring behind it is 8.9% net margin on 0.85× asset turns.
FY25 ROE is 20%, recovered from a FY24 trough of −13% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 8.9% net margin × 0.85× asset turns × 2.59× balance-sheet leverage ≈ 19.6% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 16.3% − 7.0% = a +9.3 pp spread. The 7.0% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. A spread this wide means every dollar reinvested creates more than a dollar of value — the engine compounds.
Dividend
Pediatrix Medical Group, Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
Pediatrix Medical Group, Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Pediatrix Medical Group, Inc. carries total debt of $0.6 B against shareholder equity of $0.9 B as of Mar 26, a debt-to-equity of 0.72. On the annual view that ratio went from 1.19 in FY21 to 0.72 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of $0.6 B against shareholder equity of $0.9 B — a debt-to-equity of 0.72. On the annual view, debt-to-equity went from 1.19 (FY21) to 0.72 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
6.2% of Pediatrix Medical Group, Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 5.4 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 6.2% of the float is sold short, and at typical trading volumes it would take about 5.4 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Pediatrix Medical Group, Inc.: the Z-score reads 2.16. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits in the grey band between the two. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 2.16 sits in the grey band — neither clearly safe nor clearly distressed.
The safety line in one sentence: the Z-score reads 2.16.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1AMN Healthcare Services, Inc.AMN | 64.5/100Thin evidence · provisional58% evidence | LEADER | 26.0/35 Revenue 19.8% · PAT — · OPM change 6.7 pp 62% evidence | 13.2/25 ROCE 6.9% · OPM 8.5% 76% evidence | 9.2/20 P/E 30.7× · PEG — 15% evidence | 16.1/20 RS sector 15.6% · RS bench 36.1% · 1Y 92.9%12 of 12 weeks ahead 70% evidence |
| Exact sum: 26 + 13.2 + 9.2 + 16.1 = 64.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2Tenet Healthcare CorporationTHC | 64.4/100Thin evidence · provisional58% evidence | TURNING | 23.7/35 Revenue — · PAT — · OPM change 6.2 pp 45% evidence | 16.5/25 ROCE 5.8% · OPM 23.2% 76% evidence | 11.1/20 P/E 7.2× · PEG — 15% evidence | 13.1/20 RS sector -5.5% · RS bench 13.7% · 1Y 53%3 of 12 weeks ahead 100% evidence |
| Exact sum: 23.7 + 16.5 + 11.1 + 13.1 = 64.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 3Concentra Group Holdings Parent, Inc.CON | 60.1/100Mixed-positive evidence71% evidence | BREAKING OUT | 19.8/35 Revenue 15.5% · PAT 12.9% · OPM change 0.8 pp 83% evidence | 14.8/25 ROCE 3.8% · OPM 16.8% 76% evidence | 10.2/20 P/E 15.4× · PEG — 15% evidence | 15.3/20 RS sector 0.9% · RS bench 19.9% · 1Y 43.9%9 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 14.8 + 10.2 + 15.3 = 60.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4PACS Group, Inc.PACS | 58.7/100Thin evidence · provisional56% evidence | BREAKING OUT | 21.9/35 Revenue — · PAT — · OPM change 4.7 pp 39% evidence | 13.3/25 ROCE 5.2% · OPM 8.5% 76% evidence | 9.1/20 P/E 31.5× · PEG — 15% evidence | 14.4/20 RS sector 15% · RS bench 34% · 1Y 302.2%7 of 12 weeks ahead 100% evidence |
| Exact sum: 21.9 + 13.3 + 9.1 + 14.4 = 58.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Encompass Health CorporationEHC | 55.8/100Mixed-positive evidence81% evidence | BASING | 20.6/35 Revenue 10.1% · PAT 21% · OPM change 0.7 pp 83% evidence | 15.8/25 ROCE 4.9% · OPM 19% 76% evidence | 14.4/20 P/E 16.1× · PEG 0.68 65% evidence | 5.0/20 RS sector -25.7% · RS bench -10% · 1Y -6%1 of 12 weeks ahead 100% evidence |
| Exact sum: 20.6 + 15.8 + 14.4 + 5 = 55.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Chemed CorporationCHE | 55.8/100Thin evidence · provisional58% evidence | BREAKING OUT | 18.0/35 Revenue — · PAT — · OPM change -1.7 pp 45% evidence | 15.7/25 ROCE 6.6% · OPM 12.9% 76% evidence | 9.5/20 P/E 23.4× · PEG — 15% evidence | 12.6/20 RS sector -8.7% · RS bench 9.9% · 1Y 24%7 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 15.7 + 9.5 + 12.6 = 55.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7Fresenius Medical Care AGFMS | 55.0/100Mixed-positive evidence81% evidence | TURNING | 21.6/35 Revenue -0.7% · PAT 43.7% · OPM change 1.5 pp 83% evidence | 11.4/25 ROCE 2.1% · OPM 11.7% 76% evidence | 15.8/20 P/E 11.9× · PEG 0.22 65% evidence | 6.2/20 RS sector -25.4% · RS bench -9.8% · 1Y -0.2%1 of 12 weeks ahead 100% evidence |
| Exact sum: 21.6 + 11.4 + 15.8 + 6.2 = 55 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Addus HomeCare CorporationADUS | 54.4/100Mixed-positive evidence81% evidence | BREAKING OUT | 21.2/35 Revenue 19.5% · PAT 26.6% · OPM change 0.4 pp 83% evidence | 12.3/25 ROCE 2.7% · OPM 9.4% 76% evidence | 13.7/20 P/E 17.3× · PEG 0.78 65% evidence | 7.2/20 RS sector -21.4% · RS bench -4.9% · 1Y 3.1%5 of 12 weeks ahead 100% evidence |
| Exact sum: 21.2 + 12.3 + 13.7 + 7.2 = 54.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9LifeStance Health Group, Inc.LFST | 53.3/100Mixed-positive evidence64% evidence | BREAKING OUT | 22.1/35 Revenue 16.4% · PAT — · OPM change 5 pp 62% evidence | 5.8/25 ROCE 1.2% · OPM 5.5% 76% evidence | 8.5/20 P/E 106.2× · PEG — 15% evidence | 16.9/20 RS sector 10.2% · RS bench 29.9% · 1Y 134.8%9 of 12 weeks ahead 100% evidence |
| Exact sum: 22.1 + 5.8 + 8.5 + 16.9 = 53.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10agilon health, inc.AGL | 53.2/100Mixed-positive evidence61% evidence | LEADER | 18.4/35 Revenue -2.8% · PAT — · OPM change 1.7 pp 62% evidence | 4.8/25 ROCE 1% · OPM 0.3% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 20.0/20 RS sector 87% · RS bench 109.7% · 1Y 334%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 4.8 + 10 + 20 = 53.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Healthcare Services Group, Inc.HCSG | 53.2/100Thin evidence · provisional52% evidence | FADING | 22.9/35 Revenue — · PAT — · OPM change 2.2 pp 45% evidence | 10.6/25 ROCE 3.6% · OPM 7.3% 76% evidence | 10.4/20 P/E 14.3× · PEG — 15% evidence | 9.3/20 RS sector -10.3% · RS bench 6.7% · 1Y 60.9%6 of 12 weeks ahead 70% evidence |
| Exact sum: 22.9 + 10.6 + 10.4 + 9.3 = 53.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12DaVita Inc.DVA | 53.0/100Mixed-positive evidence81% evidence | LEADER | 16.1/35 Revenue 6.7% · PAT -6.9% · OPM change 0.5 pp 83% evidence | 13.7/25 ROCE 3.3% · OPM 14.1% 76% evidence | 8.0/20 P/E 14.3× · PEG 2.08 65% evidence | 15.2/20 RS sector 13.4% · RS bench 33.4% · 1Y 76.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 16.1 + 13.7 + 8 + 15.2 = 53 · Decision use: Price leads the evidence: RS versus the benchmark is 33.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 13Acadia Healthcare Company, Inc.ACHC | 49.1/100Thin evidence · provisional58% evidence | BREAKING OUT | 14.7/35 Revenue — · PAT — · OPM change 0.1 pp 45% evidence | 7.5/25 ROCE 1.1% · OPM 5.8% 76% evidence | 9.6/20 P/E 21.2× · PEG — 15% evidence | 17.3/20 RS sector 7.7% · RS bench 27.7% · 1Y 64.6%6 of 12 weeks ahead 100% evidence |
| Exact sum: 14.7 + 7.5 + 9.6 + 17.3 = 49.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14National HealthCare CorporationNHC | 47.5/100Mixed-negative evidence81% evidence | LEADER | 16.5/35 Revenue 10.3% · PAT 16.7% · OPM change 0.2 pp 83% evidence | 10.2/25 ROCE 2.5% · OPM 8.4% 76% evidence | 9.9/20 P/E 20.3× · PEG 1.48 65% evidence | 10.9/20 RS sector 1.4% · RS bench 19.5% · 1Y 107.4%10 of 12 weeks ahead 100% evidence |
| Exact sum: 16.5 + 10.2 + 9.9 + 10.9 = 47.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Guardian Pharmacy Services, Inc.GRDN | 46.8/100Mixed-negative evidence64% evidence | TURNING | 17.2/35 Revenue 13.6% · PAT — · OPM change 1.4 pp 62% evidence | 12.6/25 ROCE 7.8% · OPM 5.3% 76% evidence | 8.7/20 P/E 45.4× · PEG — 15% evidence | 8.3/20 RS sector -6.7% · RS bench 10.7% · 1Y 103%6 of 12 weeks ahead 100% evidence |
| Exact sum: 17.2 + 12.6 + 8.7 + 8.3 = 46.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16HCA Healthcare, Inc.HCA | 44.8/100Thin evidence · provisional58% evidence | BASING | 16.2/35 Revenue — · PAT — · OPM change -0.6 pp 45% evidence | 16.4/25 ROCE 6.9% · OPM 15% 76% evidence | 10.7/20 P/E 13.1× · PEG — 15% evidence | 1.5/20 RS sector -33.7% · RS bench -19.8% · 1Y 5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.2 + 16.4 + 10.7 + 1.5 = 44.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17The Pennant Group, Inc.PNTG | 44.7/100Mixed-negative evidence75% evidence | FADING | 20.4/35 Revenue 36.6% · PAT 20.7% · OPM change 0.1 pp 83% evidence | 9.2/25 ROCE 2.3% · OPM 6.1% 76% evidence | 4.0/20 P/E 35.9× · PEG 3.03 65% evidence | 11.1/20 RS sector -3.7% · RS bench 14.3% · 1Y 48.5%6 of 12 weeks ahead 70% evidence |
| Exact sum: 20.4 + 9.2 + 4 + 11.1 = 44.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Aveanna Healthcare Holdings Inc.AVAH | 44.5/100Thin evidence · provisional58% evidence | BREAKING OUT | 11.5/35 Revenue — · PAT — · OPM change -2.9 pp 45% evidence | 11.8/25 ROCE 4.8% · OPM 10.7% 76% evidence | 11.4/20 P/E 5.4× · PEG — 15% evidence | 9.8/20 RS sector -14.2% · RS bench 3.6% · 1Y 52.4%7 of 12 weeks ahead 100% evidence |
| Exact sum: 11.5 + 11.8 + 11.4 + 9.8 = 44.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Universal Health Services, Inc.UHS | 44.3/100Thin evidence · provisional58% evidence | BASING | 16.4/35 Revenue — · PAT — · OPM change 0.1 pp 45% evidence | 14.1/25 ROCE 4.1% · OPM 11.2% 76% evidence | 11.3/20 P/E 6.1× · PEG — 15% evidence | 2.5/20 RS sector -35.5% · RS bench -21.5% · 1Y -2.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.4 + 14.1 + 11.3 + 2.5 = 44.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Option Care Health, Inc.OPCH | 43.4/100Thin evidence · provisional58% evidence | TURNING | 17.0/35 Revenue — · PAT — · OPM change -0.5 pp 45% evidence | 11.3/25 ROCE 3.3% · OPM 5.4% 76% evidence | 10.1/20 P/E 15.8× · PEG — 15% evidence | 5.0/20 RS sector -37.2% · RS bench -23.5% · 1Y -16%2 of 12 weeks ahead 100% evidence |
| Exact sum: 17 + 11.3 + 10.1 + 5 = 43.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21Pediatrix Medical Group, Inc.this pageMD | 43.3/100Mixed-negative evidence74% evidence | FADING | 17.5/35 Revenue -2.2% · PAT — · OPM change 1.7 pp 62% evidence | 10.2/25 ROCE 2.5% · OPM 8.7% 76% evidence | 9.9/20 P/E 10.4× · PEG 1.7 65% evidence | 5.7/20 RS sector -11.9% · RS bench 5.1% · 1Y 72.4%7 of 12 weeks ahead 100% evidence |
| Exact sum: 17.5 + 10.2 + 9.9 + 5.7 = 43.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22The Ensign Group, Inc.ENSG | 42.2/100Thin evidence · provisional58% evidence | BASING | 17.7/35 Revenue — · PAT — · OPM change 0.4 pp 45% evidence | 12.2/25 ROCE 2.7% · OPM 9% 76% evidence | 9.3/20 P/E 25.1× · PEG — 15% evidence | 3.0/20 RS sector -27.5% · RS bench -12.6% · 1Y 9.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.7 + 12.2 + 9.3 + 3 = 42.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23Select Medical Holdings CorporationSEM | 40.7/100Mixed-negative evidence75% evidence | 11.1/35 Revenue 5.8% · PAT -20% · OPM change -1.4 pp 83% evidence | 9.7/25 ROCE 2% · OPM 6.9% 76% evidence | 13.1/20 P/E 15.4× · PEG 0.93 65% evidence | 6.8/20 RS sector -22.8% · RS bench 1.5% · 1Y 9%0 of 7 weeks ahead to 2026-07-02 70% evidence | |
| Exact sum: 11.1 + 9.7 + 13.1 + 6.8 = 40.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 24InnovAge Holding Corp.INNV | 39.7/100Thin evidence · provisional58% evidence | BREAKING OUT | 10.8/35 Revenue 14.2% · PAT — · OPM change -6.8 pp 62% evidence | 3.6/25 ROCE -8.8% · OPM -11.5% 76% evidence | 8.6/20 P/E 103.8× · PEG — 15% evidence | 16.7/20 RS sector 20% · RS bench 39.9% · 1Y 227.8%7 of 12 weeks ahead 70% evidence |
| Exact sum: 10.8 + 3.6 + 8.6 + 16.7 = 39.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25Brookdale Senior Living Inc.BKD | 39.3/100Mixed-negative evidence61% evidence | TURNING | 17.0/35 Revenue -0.4% · PAT — · OPM change 3.2 pp 62% evidence | 5.0/25 ROCE 0.9% · OPM 6.8% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 7.3/20 RS sector -10.3% · RS bench 6.1% · 1Y 97.4%2 of 12 weeks ahead 100% evidence |
| Exact sum: 17 + 5 + 10 + 7.3 = 39.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Ardent Health, Inc.ARDT | 39.2/100Mixed-negative evidence65% evidence | TURNING | 14.3/35 Revenue 6.7% · PAT -26.8% · OPM change 0.6 pp 83% evidence | 8.7/25 ROCE 1.9% · OPM 5.1% 76% evidence | 11.0/20 P/E 9× · PEG — 15% evidence | 5.2/20 RS sector -24.1% · RS bench -7.7% · 1Y -9.6%2 of 12 weeks ahead 70% evidence |
| Exact sum: 14.3 + 8.7 + 11 + 5.2 = 39.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Astrana Health, Inc.ASTH | 37.9/100Mixed-negative evidence81% evidence | FADING | 14.2/35 Revenue 56.8% · PAT -20.5% · OPM change -0.3 pp 83% evidence | 7.3/25 ROCE 2.2% · OPM 3% 76% evidence | 10.5/20 P/E 40.2× · PEG 1.17 65% evidence | 5.9/20 RS sector -10.4% · RS bench 6.4% · 1Y 27%10 of 12 weeks ahead 100% evidence |
| Exact sum: 14.2 + 7.3 + 10.5 + 5.9 = 37.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Surgery Partners, Inc.SGRY | 36.7/100Mixed-negative evidence61% evidence | FADING | 13.9/35 Revenue 5.4% · PAT — · OPM change 0.1 pp 62% evidence | 7.2/25 ROCE 0.9% · OPM 8.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 5.6/20 RS sector -31% · RS bench -15.8% · 1Y -33.8%7 of 12 weeks ahead 100% evidence |
| Exact sum: 13.9 + 7.2 + 10 + 5.6 = 36.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Sonida Senior Living, Inc.SNDA | 34.2/100Adverse evidence64% evidence | FADING | 13.0/35 Revenue 25.5% · PAT — · OPM change -20.5 pp 62% evidence | 3.8/25 ROCE -1.9% · OPM -23.6% 76% evidence | 11.5/20 P/E 1.9× · PEG — 15% evidence | 5.9/20 RS sector -11.4% · RS bench 5.4% · 1Y 58.1%5 of 12 weeks ahead 100% evidence |
| Exact sum: 13 + 3.8 + 11.5 + 5.9 = 34.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30COMPASS Pathways plcCMPS | 48.3/100Thin evidence · provisional47% evidence | LEADER | 19.8/35 Revenue — · PAT — · OPM change — 33% evidence | 5.0/25 ROCE -12.9% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 13.5/20 RS sector 18.2% · RS bench 37.9% · 1Y 168.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 5 + 10 + 13.5 = 48.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Pediatrix Medical Group, Inc.'s stock price today?
Pediatrix Medical Group, Inc. trades at $24.7, +106.3% over the past year. The company is valued at $2.0 B. The stock sits at 81% of its 52-week range of $16–$27, +11.4% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 53 weeks in. — as of 5 August 2026.
What were Pediatrix Medical Group, Inc.'s latest quarterly results?
Pediatrix Medical Group, Inc. reported revenue of $0.5 B and net profit of $0.0 B for the Mar 26 quarter. Revenue rose 4.3% and profit rose 50.0% year on year. Earnings per share were $0.36. The operating margin was 8.3%, 1.8 pp higher than a year earlier. — as of 5 August 2026.
What is Pediatrix Medical Group, Inc.'s revenue?
Pediatrix Medical Group, Inc. reported revenue of $0.5 B in the Mar 26 quarter, +4.3% year on year. For the full FY25 fiscal year, revenue was $1.9 B (−5.0%). Over the last 4 years revenue compounded at 0.0% a year. — as of 5 August 2026.
What is Pediatrix Medical Group, Inc.'s profit?
Pediatrix Medical Group, Inc. earned $0.0 B of net profit in the Mar 26 quarter, +50.0% year on year. Full-year FY25 profit was $0.2 B. The operating margin ran 8.3% in the latest quarter. — as of 5 August 2026.
What is Pediatrix Medical Group, Inc.'s market cap?
Pediatrix Medical Group, Inc.'s market capitalisation is $2.0 B at a stock price of $24.7. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
What is Pediatrix Medical Group, Inc.'s P/E ratio?
Pediatrix Medical Group, Inc. trades at a P/E of 11.8×, at the 45th percentile of its own 4-year range, against a long-run median of 12.0×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.
Does Pediatrix Medical Group, Inc. pay a dividend?
No — Pediatrix Medical Group, Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.
Is Pediatrix Medical Group, Inc. overvalued?
On its own history, Pediatrix Medical Group, Inc. looks mid-range against its own history: its P/E of 11.8× sits at the 45th percentile of its 4-year range (long-run median 12.0×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 5 August 2026.
Is Pediatrix Medical Group, Inc. growing?
Yes — Pediatrix Medical Group, Inc. is growing: latest-quarter revenue +4.3% year on year, profit +50.0%, and the margin +1.8 pp at 8.3%. The 4-year compound rates are 0.0% (revenue) and 6.9% (profit). The earnings engine currently reads: improving — as of 5 August 2026.
How is Pediatrix Medical Group, Inc. performing?
Pediatrix Medical Group, Inc. is in a confirmed uptrend, 53 weeks in. Its latest quarter's revenue rose 4.3% and profit rose 50.0% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 10 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
What stage is Pediatrix Medical Group, Inc. in?
Improving — profit growth bottomed 7 quarters ago at −100.0% and has held its recovery at +50.0% (single-quarter readings), ROCE lifting at 13.1%. The read comes from the last 12 quarters of growth (revenue growth −2.0% latest, profit growth +50.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.
Is Pediatrix Medical Group, Inc. in an uptrend?
Yes — the price is in a confirmed uptrend (week 53 of stage 2), trading +11.4% versus its 200-day average and at 81% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is Pediatrix Medical Group, Inc. beating the market?
On recent form, yes — Pediatrix Medical Group, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 10 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved −67% against the S&P 500's +263% — behind the index over the full window. — as of 5 August 2026.
Will Pediatrix Medical Group, Inc.'s stock price go up?
This page publishes no price forecast for Pediatrix Medical Group, Inc. What it measures instead: the stock price is $24.7, the price is in a confirmed uptrend 53 weeks in. Its P/E of 11.8× sits at the 45th percentile of its own 4-year range. — as of 5 August 2026.
Is the market betting against Pediatrix Medical Group, Inc.?
Somewhat — short interest is 6.2% of Pediatrix Medical Group, Inc.'s tradable float, about 5.4 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Does Pediatrix Medical Group, Inc. have too much debt?
It is moderate — Pediatrix Medical Group, Inc.'s debt-to-equity is 0.70. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.
What is Pediatrix Medical Group, Inc.'s capex?
Pediatrix Medical Group, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 5 August 2026.
What is Pediatrix Medical Group, Inc.'s cash flow?
Pediatrix Medical Group, Inc. generated $0.3 B of operating cash flow in FY25 and $0.3 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $0.2 B, so operating cash ran ahead of profit. — as of 5 August 2026.
Is Pediatrix Medical Group, Inc.'s profit real cash?
Yes — over the last 3 fiscal years, 141% of Pediatrix Medical Group, Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $0.3 B against reported profit of $0.2 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.
How financially safe is Pediatrix Medical Group, Inc.?
On the balance sheet, the Z-score reads 2.16 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is in the grey band — neither clearly safe nor clearly distressed. — as of 5 August 2026.
Where is Pediatrix Medical Group, Inc. in its business cycle?
Pediatrix Medical Group, Inc.'s FY25 operating margin was 11.0%, against a 5-year band of −3.5%–11.5%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 8.3%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the Pediatrix Medical Group, Inc. story?
Biggest watch item: the price is already 53 weeks into its uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is Pediatrix Medical Group, Inc. a stock worth studying right now?
This is not investment advice. The machine read: Pediatrix Medical Group, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.